MEDINDIA
English
हिन्दी
Español
français
中文
Email
4-Phenylbutyric Acid
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Flurandrenolide.
Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Flurandrenolide.
Acemetacin
The risk or severity of adverse effects can be increased when Acemetacin is combined with Flurandrenolide.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flurandrenolide.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Flurandrenolide.
Aldesleukin
Flurandrenolide may decrease the antineoplastic activities of Aldesleukin.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Flurandrenolide.
Aloxiprin
The risk or severity of adverse effects can be increased when Aloxiprin is combined with Flurandrenolide.
Aluminum
The bioavailability of Flurandrenolide can be decreased when combined with Aluminium.
Aluminum Hydroxide
The bioavailability of Flurandrenolide can be decreased when combined with Aluminum hydroxide.
aluminum hydroxide, dried (USP)
The bioavailability of Flurandrenolide can be decreased when combined with Aluminum hydroxide.
Aluminum Magnesium Silicate
The bioavailability of Flurandrenolide can be decreased when combined with Almasilate.
Ambenonium
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ambenonium.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flurandrenolide.
Amiodarone
The serum concentration of Flurandrenolide can be increased when it is combined with Amiodarone.
Amphotericin B
Flurandrenolide may increase the hypokalemic activities of Amphotericin B.
amphotericin B liposomal
Flurandrenolide may increase the hypokalemic activities of Amphotericin B.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Anthrax immune globulin human.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Flurandrenolide.
Apalutamide
The serum concentration of Flurandrenolide can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Flurandrenolide.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Flurandrenolide.
Aprepitant
The serum concentration of Flurandrenolide can be increased when it is combined with Aprepitant.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flurandrenolide.
Atazanavir
The serum concentration of Flurandrenolide can be increased when it is combined with Atazanavir.
Atracurium Besylate
Atracurium besylate may increase the adverse neuromuscular activities of Flurandrenolide.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Flurandrenolide.
Azosemide
Flurandrenolide may increase the hypokalemic activities of Azosemide.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Flurandrenolide.
BCG Vaccine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with BCG vaccine.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Bacillus calmette-guerin substrain tice live antigen.
Bendroflumethiazide
Flurandrenolide may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic Acid
The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Flurandrenolide.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Flurandrenolide.
Bismuth Subcitrate
The bioavailability of Flurandrenolide can be decreased when combined with Bismuth Subcitrate.
Boceprevir
The serum concentration of Flurandrenolide can be increased when it is combined with Boceprevir.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Flurandrenolide.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Flurandrenolide.
Bumetanide
Flurandrenolide may increase the hypokalemic activities of Bumetanide.
Calcitriol
The therapeutic efficacy of Calcitriol can be decreased when used in combination with Flurandrenolide.
Calcium Carbonate
The bioavailability of Flurandrenolide can be decreased when combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The bioavailability of Flurandrenolide can be decreased when combined with Calcium Carbonate.
Capromab Pendetide
Flurandrenolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Carbamazepine
The serum concentration of Flurandrenolide can be decreased when it is combined with Carbamazepine.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Flurandrenolide.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Flurandrenolide.
Ceritinib
Flurandrenolide may increase the hyperglycemic activities of Ceritinib.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Flurandrenolide.
Chlorothiazide
Flurandrenolide may increase the hypokalemic activities of Chlorothiazide.
Chlorotrianisene
The serum concentration of Flurandrenolide can be increased when it is combined with Chlorotrianisene.
Chlorthalidone
Flurandrenolide may increase the hypokalemic activities of Chlorthalidone.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flurandrenolide.
Cinoxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Cinoxacin.
Clarithromycin
The serum concentration of Flurandrenolide can be increased when it is combined with Clarithromycin.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Flurandrenolide.
Cobicistat
The serum concentration of Flurandrenolide can be increased when it is combined with Cobicistat.
Colesevelam
Colesevelam can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Corticorelin Ovine
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flurandrenolide.
Corticorelin Ovine Triflutate
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flurandrenolide.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Flurandrenolide.
Cyclopenthiazide
Flurandrenolide may increase the hypokalemic activities of Cyclopenthiazide.
Danazol
Flurandrenolide may increase the fluid retaining activities of Danazol.
Darunavir
The serum concentration of Flurandrenolide can be increased when it is combined with Darunavir.
Deferasirox
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Deferasirox.
Demecarium
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Demecarium.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Flurandrenolide.
Dienestrol
The serum concentration of Flurandrenolide can be increased when it is combined with Dienestrol.
Diethylstilbestrol
The serum concentration of Flurandrenolide can be increased when it is combined with Diethylstilbestrol.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Flurandrenolide.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Flurandrenolide.
Distigmine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Distigmine.
Donepezil
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Donepezil.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Flurandrenolide.
Echothiophate
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Echothiophate.
Edrophonium
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Edrophonium.
Enoxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Enoxacin.
Enzalutamide
The serum concentration of Flurandrenolide can be decreased when it is combined with Enzalutamide.
Equol, (-)-
The serum concentration of Flurandrenolide can be increased when it is combined with Equol.
Estradiol
The serum concentration of Flurandrenolide can be increased when it is combined with Estradiol.
Estradiol acetate
The serum concentration of Flurandrenolide can be increased when it is combined with Estradiol acetate.
Estradiol Cypionate
The serum concentration of Flurandrenolide can be increased when it is combined with Estradiol cypionate.
Estradiol Valerate
The serum concentration of Flurandrenolide can be increased when it is combined with Estradiol valerate.
Estriol
The serum concentration of Flurandrenolide can be increased when it is combined with Estriol.
Estrogens, Conjugated (USP)
The serum concentration of Flurandrenolide can be increased when it is combined with Conjugated estrogens.
Estrogens, Esterified (USP)
The serum concentration of Flurandrenolide can be increased when it is combined with Estrogens, esterified.
Estrone
The serum concentration of Flurandrenolide can be increased when it is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Flurandrenolide.
Ethacrynate
Flurandrenolide may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Flurandrenolide may increase the hypokalemic activities of Etacrynic acid.
Ethinyl Estradiol
The serum concentration of Flurandrenolide can be increased when it is combined with Ethinyl Estradiol.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Flurandrenolide.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Flurandrenolide.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Flurandrenolide.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Flurandrenolide.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Flurandrenolide.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Flurandrenolide.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Flurandrenolide.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Flurandrenolide.
Fleroxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Flurandrenolide.
Flumequine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Flumequine.
Fluoxymesterone
Flurandrenolide may increase the fluid retaining activities of Fluoxymesterone.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Flurandrenolide.
Fosaprepitant
The serum concentration of Flurandrenolide can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The serum concentration of Flurandrenolide can be decreased when it is combined with Fosphenytoin.
Furosemide
Flurandrenolide may increase the hypokalemic activities of Furosemide.
Galantamine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gallamine Triethiodide.
Gatifloxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gatifloxacin.
Gatifloxacin Anhydrous
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gatifloxacin.
Gemifloxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gemifloxacin.
Gemifloxacin Mesylate
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gemifloxacin.
Genistein
The serum concentration of Flurandrenolide can be increased when it is combined with Genistein.
Ginkgo biloba extract
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ginkgo biloba.
Glycerol Phenylbutyrate
The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Flurandrenolide.
Grepafloxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Grepafloxacin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Hepatitis B Vaccine (Recombinant).
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flurandrenolide.
Hyaluronidase, Ovine
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flurandrenolide.
Hydrochlorothiazide
Flurandrenolide may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Flurandrenolide may increase the hypokalemic activities of Hydroflumethiazide.
Hydrotalcite
The bioavailability of Flurandrenolide can be decreased when combined with Hydrotalcite.
Hypoxis hemerocallidea root extract
The serum concentration of Flurandrenolide can be decreased when it is combined with St. John's Wort.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Flurandrenolide.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Flurandrenolide.
Idelalisib
The serum concentration of Flurandrenolide can be increased when it is combined with Idelalisib.
Indacaterol
Indacaterol may increase the hypokalemic activities of Flurandrenolide.
Indapamide
Flurandrenolide may increase the hypokalemic activities of Indapamide.
Indinavir
The serum concentration of Flurandrenolide can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Flurandrenolide can be increased when it is combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Flurandrenolide.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Flurandrenolide.
Isoflurophate
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Isoflurophate.
Isoniazid
The serum concentration of Isoniazid can be decreased when it is combined with Flurandrenolide.
Itraconazole
The serum concentration of Flurandrenolide can be increased when it is combined with Itraconazole.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Flurandrenolide.
Ketoconazole
The serum concentration of Flurandrenolide can be increased when it is combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flurandrenolide.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Flurandrenolide.
Lacidipine
The serum concentration of Lacidipine can be decreased when it is combined with Flurandrenolide.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Flurandrenolide.
Levofloxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin.
Levofloxacin Anhydrous
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Flurandrenolide.
Lopinavir
The serum concentration of Flurandrenolide can be increased when it is combined with Lopinavir.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Flurandrenolide.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Flurandrenolide.
Lumacaftor
The serum concentration of Flurandrenolide can be decreased when it is combined with Lumacaftor.
Magaldrate
The bioavailability of Flurandrenolide can be decreased when combined with Magaldrate.
Magnesium Hydroxide
The bioavailability of Flurandrenolide can be decreased when combined with Magnesium hydroxide.
Magnesium Oxide
The bioavailability of Flurandrenolide can be decreased when combined with Magnesium oxide.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flurandrenolide.
Magnesium Trisilicate
The bioavailability of Flurandrenolide can be decreased when combined with Magnesium Trisilicate.
Malathion
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Malathion.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Flurandrenolide.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flurandrenolide.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flurandrenolide.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Flurandrenolide.
Mefloquine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Mefloquine.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Flurandrenolide.
Memantine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Memantine.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Flurandrenolide.
Mesterolone
Flurandrenolide may increase the fluid retaining activities of Mesterolone.
Mestranol
The serum concentration of Flurandrenolide can be increased when it is combined with Mestranol.
Methyclothiazide
Flurandrenolide may increase the hypokalemic activities of Methyclothiazide.
Methyl Salicylate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flurandrenolide.
Methyltestosterone
Flurandrenolide may increase the fluid retaining activities of Methyltestosterone.
Metoclopramide
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Metoclopramide.
Metolazone
Flurandrenolide may increase the hypokalemic activities of Metolazone.
Mifepristone
The therapeutic efficacy of Flurandrenolide can be decreased when used in combination with Mifepristone.
Minaprine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Minaprine.
Mitotane
The serum concentration of Flurandrenolide can be decreased when it is combined with Mitotane.
Mivacurium
Mivacurium may increase the adverse neuromuscular activities of Flurandrenolide.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flurandrenolide.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flurandrenolide.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flurandrenolide.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Flurandrenolide.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Flurandrenolide.
Nalidixic Acid
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Nalidixic Acid.
Nandrolone
Flurandrenolide may increase the fluid retaining activities of Nandrolone.
Nandrolone Decanoate
Flurandrenolide may increase the fluid retaining activities of Nandrolone decanoate.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Flurandrenolide.
Nefazodone
The serum concentration of Flurandrenolide can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Flurandrenolide can be increased when it is combined with Nelfinavir.
Neostigmine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Neostigmine.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Flurandrenolide.
Nevirapine
The serum concentration of Flurandrenolide can be decreased when it is combined with Nevirapine.
Nicorandil
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Nicorandil.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flurandrenolide.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Flurandrenolide.
Norfloxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Norfloxacin.
O-PHENANTHROLINE
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with 1,10-Phenanthroline.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Flurandrenolide.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Flurandrenolide.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Flurandrenolide.
Oxandrolone
Flurandrenolide may increase the fluid retaining activities of Oxandrolone.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Flurandrenolide.
Oxymetholone
Flurandrenolide may increase the fluid retaining activities of Oxymetholone.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flurandrenolide.
Parecoxib
The risk or severity of adverse effects can be increased when Parecoxib is combined with Flurandrenolide.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Flurandrenolide.
Pefloxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pefloxacin.
Pentobarbital
The serum concentration of Flurandrenolide can be decreased when it is combined with Pentobarbital.
Phenobarbital
The serum concentration of Flurandrenolide can be decreased when it is combined with Phenobarbital.
Phenylacetic Acid
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Flurandrenolide.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flurandrenolide.
Phenylbutyrate
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Flurandrenolide.
Phenytoin
The serum concentration of Flurandrenolide can be decreased when it is combined with Phenytoin.
Physostigmine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Physostigmine.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flurandrenolide.
Piretanide
Flurandrenolide may increase the hypokalemic activities of Piretanide.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Flurandrenolide.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Flurandrenolide.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Flurandrenolide.
Polyestradiol Phosphate
The serum concentration of Flurandrenolide can be increased when it is combined with Polyestradiol phosphate.
Polythiazide
Flurandrenolide may increase the hypokalemic activities of Polythiazide.
Posaconazole
The serum concentration of Flurandrenolide can be increased when it is combined with Posaconazole.
Primidone
The serum concentration of Flurandrenolide can be decreased when it is combined with Primidone.
Promestriene
The serum concentration of Flurandrenolide can be increased when it is combined with Promestriene.
Pyridostigmine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pyridostigmine.
Pyridostigmine Bromide
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pyridostigmine.
Quinestrol
The serum concentration of Flurandrenolide can be increased when it is combined with Quinestrol.
Quinethazone
Flurandrenolide may increase the hypokalemic activities of Quinethazone.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rabies virus inactivated antigen, A.
Rapacuronium
Rapacuronium may increase the adverse neuromuscular activities of Flurandrenolide.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Flurandrenolide.
Rifabutin
The serum concentration of Flurandrenolide can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Flurandrenolide can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Flurandrenolide can be decreased when it is combined with Rifapentine.
Rivastigmine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rivastigmine.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Flurandrenolide.
Rosoxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rosoxacin.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rubella virus vaccine.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Flurandrenolide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Flurandrenolide.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Salmonella typhi ty21a live antigen.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Flurandrenolide.
Saquinavir
The serum concentration of Flurandrenolide can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Flurandrenolide can be increased when it is combined with Saquinavir.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Flurandrenolide.
Sodium Bicarbonate
The bioavailability of Flurandrenolide can be decreased when combined with Sodium bicarbonate.
Sparfloxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Sparfloxacin.
ST. JOHN'S WORT EXTRACT
The serum concentration of Flurandrenolide can be decreased when it is combined with St. John's Wort.
Stanozolol
Flurandrenolide may increase the fluid retaining activities of Stanozolol.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flurandrenolide.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Flurandrenolide.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Flurandrenolide.
synthetic conjugated estrogens, A
The serum concentration of Flurandrenolide can be increased when it is combined with Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
The serum concentration of Flurandrenolide can be increased when it is combined with Synthetic Conjugated Estrogens, B.
Tacrine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Tacrine.
Telaprevir
The serum concentration of Telaprevir can be decreased when it is combined with Flurandrenolide.
Telithromycin
The serum concentration of Flurandrenolide can be increased when it is combined with Telithromycin.
Temafloxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Temafloxacin.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Flurandrenolide.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Flurandrenolide.
Testosterone
Flurandrenolide may increase the fluid retaining activities of Testosterone.
Testosterone Cypionate
Flurandrenolide may increase the fluid retaining activities of Testosterone cypionate.
Testosterone Enanthate
Flurandrenolide may increase the fluid retaining activities of Testosterone enanthate.
Testosterone Propionate
Flurandrenolide may increase the fluid retaining activities of Testosterone propionate.
Testosterone Undecanoate
Flurandrenolide may increase the fluid retaining activities of Testosterone undecanoate.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flurandrenolide.
Tibolone
The serum concentration of Flurandrenolide can be increased when it is combined with Tibolone.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flurandrenolide.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Flurandrenolide.
Torsemide
Flurandrenolide may increase the hypokalemic activities of Torasemide.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Flurandrenolide.
Trichlormethiazide
Flurandrenolide may increase the hypokalemic activities of Trichlormethiazide.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flurandrenolide.
Tromethamine
The bioavailability of Flurandrenolide can be decreased when combined with Tromethamine.
Trovafloxacin
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Trovafloxacin.
Tubocurarine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Tubocurarine.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Flurandrenolide.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Varicella Zoster Vaccine (Live/Attenuated).
Voriconazole
The serum concentration of Flurandrenolide can be increased when it is combined with Voriconazole.
Warfarin
Flurandrenolide may increase the anticoagulant activities of Warfarin.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Yellow Fever Vaccine.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Flurandrenolide.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Flurandrenolide.
